ARCHIVES

Promising Results For Glivec In CML Continue, FDA Grants Priority Review

This article is from The Cancer Letter archive.

Vol. 24 No. 4 | April 27, 2001

Download PDF Visit The Full Archive

Related Articles

Officials: Poisoning Unrelated to MD Anderson; Critics Allege Dysfunction in Handling of Affair

September 19, 2014

DCT Board Okays Consideration Of New New Heavy Particle Therapy Studies

March 8, 1985

Bush Asks Hammer To Probe FDA Regulation Of Anticancer Drugs

June 17, 1988

Clinical Trials Approved By NCI Last Month

March 29, 2002

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

DCT Board Approves Proposals For Increased Efforts With Biological Response Modifiers, Oks Contracts

November 9, 1979